Obesity and type 2 diabetes rarely occur alone. That's why it's important to have treatment options that address different patient's needs. This is the thinking behind our work at the upcoming #EASD2026# conference in Milan, Italy. Read more about our approach:

Adults with type 2 diabetes on our investigational triple agonist saw significant A1C reductions at 40 weeks in the TRANSCEND-T2D-1 trial. Results presented today at #ADA2026# and published simultaneously in @TheLancet. Read more:

Millions of people live with diabetes and obesity, and the science keeps moving forward. This month, researchers and clinicians will gather in Milan for #EASD2026#. We'll be there, sharing new findings as we work together to advance cardiometabolic health:

Nearly half of those managing diabetes are forced to shell out thousands a year to afford the insulin they need to live. This cannot stand. We must cap insulin at $35 a month to ensure everyone can afford the life-saving medication they need.

For International Audiences: Patients with diabetes often represent a more complex population, but REDUCER I showed that #ShockwaveReducer# delivers angina relief equally for patients suffering from diabetes.​ The trial demonstrated that device implantation was safe and just as effective at improving angina symptoms and quality of life in patients with and without diabetes.​ Explore the REDUCER I Diabetes Sub-Analysis:  de Silva, R. Results from the REDUCER-I Study. ESC 2025​ Safety Info: ​ CAUTION: Investigational Device. Limited by U.S. and Canadian law to investigational use. The Reducer is commercially available in certain countries outside the U.S. and Canada.